Novo Nordisk Cuts Deep: A New Weight-Loss Strategy?

Novo Nordisk, maker of Wegovy and Ozempic, slashes 9,000 jobs worldwide! Find out why the pharmaceutical giant is making massive cuts to streamline operations, save $1.25 billion, and reinvest in the booming weight-loss drug market amid rising competition. Is this a strategic move or a sign of trouble for the Danish company and its employees? Hosted on Acast. See acast.com/privacy for more information.